XAGE-3 Inhibitors
Inhibitors targeting the functional activity of XAGE-3 play a crucial role in modulating the biological processes that this protein is involved in, particularly in the realm of cancer where XAGE-3 has been implicated. Proteasome inhibitors, such as those that impede the degradation of ubiquitin-conjugated proteins, lead to the stabilization of tumor suppressors and pro-apoptotic factors. This accumulation can trigger increased apoptosis and hinder cell proliferation, processes in which XAGE-3 is engaged. Furthermore, histone deacetylase inhibitors that modify chromatin structure influence gene expression and cell cycle dynamics, which may attenuate the proliferation of cells expressing XAGE-3, thus indirectly diminishing its functional activity. Additionally, compounds that disrupt DNA repair mechanisms or induce DNA damage directly influence cell survival pathways. These agents can cause cell death in populations that depend on XAGE-3 for growth or survival, effectively curtailing its role in these cells.
Other inhibitors achieve indirect suppression of XAGE-3 through the targeted inhibition of key kinases and signaling molecules involved in cell growth and angiogenesis. Kinase inhibitors that blunt the activity of specific signaling pathways result in a reduction of cellular proliferation, thereby potentially limiting the functional activity of XAGE-3 in tumor cells. Similarly, inhibitors of mTOR, a pivotal regulator of cell growth, can impede the proliferation and survival of cells that rely on XAGE-3, affecting the protein's overall activity. Agents that engage with the molecular machinery of apoptosis, such as those stabilizing p53or inducing DNA damage through the formation of DNA adducts, also contribute to the reduction of XAGE-3 activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
This proteasome inhibitor affects the degradation of various proteins, including tumor suppressors and pro-apoptotic factors. By stabilizing these proteins, bortezomib can lead to increased apoptosis and reduced proliferation, processes in which XAGE-3 has been implicated. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
As a histone deacetylase inhibitor, trichostatin A modifies chromatin structure and affects the expression of various genes. This can lead to altered cell cycle progression, potentially decreasing the expression or function of XAGE-3. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitin-conjugated proteins, possibly leading to the reduction of cell proliferation, thereby indirectly inhibiting XAGE-3 function. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
A histone deacetylase inhibitor. Can affect gene expression profiles and cell cycle progression, possibly reducing the proliferation of cells that express XAGE-3. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $52.00 $87.00 | 7 | |
By inhibiting aldehyde dehydrogenase, disulfiram can alter cellular metabolism and redox states, which may influence the cell cycle and proliferation, indirectly affecting the functions of XAGE-3. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
Olaparib, a PARP inhibitor, affects DNA repair mechanisms. In cells that rely on XAGE-3 for growth or survival, compromised DNA repair may lead to cell death and thus inhibit XAGE-3-related processes. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $56.00 $212.00 $764.00 | 24 | |
As an MDM2 antagonist, nutlin-3 stabilizes p53, leading to cell cycle arrest or apoptosis in p53-responsive cells. Since XAGE-3 is associated with cancer, stabilizing p53 may reduce the functional activity of XAGE-3. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin forms DNA adducts leading to apoptosis. In cells expressing XAGE-3, DNA damage-induced apoptosis can result in an overall decrease of XAGE-3 function. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. Cells reliant on XAGE-3 for growth may exhibit decreased survival, indirectly inhibiting XAGE-3. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets various cell signaling pathways. By inhibiting these pathways, it can reduce cellular proliferation and angiogenesis, potentially decreasing the functional activity of XAGE-3 in certain cells. | ||||||